Sector News

Dr Jessie English joins Merck

January 26, 2016
Life sciences

Merck Jessie EnglishMerck KGaA has appointed Dr Jessie English as its new vice president of discovery, transnational innovation platform immuno-oncology.

She will take up her new role on 16 February, when she will lead the discovery team’s efforts in the exploration of disease targets and translating these into patient care.

Dr English joins Merck from the Belfer Institute for Applied Cancer Sciences at Havard Medical School’s Dana-Farber Cancer Institute where she had been head of research since March 2012.

During her two decades of work in oncology and immune-oncology research, she has also served as vice president of kinase biology at ArQule, oncology site lead for external discoveries at Merck Research Laboratories.

Prior to that she held leadership positions at both Pfizer Research and Schering-Plough Research Institute.

Source: PMLive

Related News

July 31, 2021

Lonza positions collagen as “key” to future of joint health market

Life sciences

NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.

July 31, 2021

Novo Holdings co-leads Hemab’s US$ 55M Series A to advance next generation therapeutics for bleeding and thrombosis disorders

Life sciences

The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.

July 31, 2021

BD acquires Tepha to drive new innovations in soft tissue repair and regeneration

Life sciences

BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.

Send this to a friend